CHARISMA Expansion Study

Community Health Clinic Model for Agency in Relationships and Safer Microbicide Adherence (CHARISMA) Expansion Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04092114

Acronym

CHARISMA

Enrollment

407

Registered

2019-09-17

Start date

2018-10-15

Completion date

2020-05-25

Last updated

2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-exposure Prophylaxis (PrEP) Adherence, Relationship Dynamics

Keywords

PrEP (Pre-exposure Prophylaxis), HIV prevention, Intimate Partner Violence (IPV)

Brief summary

Detailed description

The CHARISMA Expansion Study is a two-arm, randomized (1:1), controlled study of a behavioral intervention-the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence (CHARISMA)-which aims to reduce social harms (SHs) and intimate partner violence (IPV), increase healthy relationship dynamics and oral PrEP TDF/FTC (hereafter called PrEP) adherence among enrolled women. This study is an expansion of the CHARISMA intervention pilot study which was appended to the Microbicide Trials Network (MTN)-025 HOPE study and will conclude in 2018. CHARISMA is defined by the use of a tool, called the CHARISMA HEAlthy Relationship Assessment Tool (HEART) used in combination with three counselling modules: * Module A: General Partner Communication and Relationship Skills * Module B: Partner Disclosure and Communication around PrEP Use * Module C: Responding to Intimate Partner Violence and Safety Planning The HEART will be used to assess the status of women's relationships and experience of IPV in the intervention arm. The HEART, previously piloted in HOPE, is a tool used to facilitate assessment of, and response to, the range of positive and negative effects of HIV prevention product use experienced by women in intimate partner relationships. In September 2015, the World Health Organization issued guidelines recommending PrEP be offered to all persons at substantial HIV risk (defined as HIV incidence rate above 3%) worldwide. In sub-Saharan Africa, women account for 58% of the total number of people living with HIV. Given the high HIV incidence and evidence for high potential effectiveness of PrEP when adherence to product use is high, PrEP delivery, adherence, and associated male partner dynamics should be evaluated among a broad age range of women. This study will enroll sexually active, HIV-uninfected women, who are trial naïve, non-pregnant and aged 18-45 years (inclusive). PrEP, delivered according to national guidelines, IPV screening using the WHO Violence Against Women Survey (VAWS) and referrals for care will be offered to all eligible participants as Standard of Care (SOC) in the control arm. CHARISMA intervention arm participants will receive in-person counselling as part of the CHARISMA intervention to help them assess and build support for PrEP use within their relationships. SHs, IPV, relationship dynamics (e.g. communication, support) and PrEP adherence will be compared across the two arms. Social harms are defined as non-clinical trial related adverse events that result in psychosocial, social, or physical harm among women. Design: Two-arm, randomized (1:1), controlled study of a behavioral intervention to increase adherence to daily oral PrEP, improve partner relationships (communication and support) and reduce SH and IPV. A PrEP delivery project will be established in accordance with national guidelines in South African Department of Health (DoH) PrEP guidelines supplemented by the addition of the CHARISMA intervention. Participants presenting for enrolment will be randomized to one of two study arms below: 1. Control: Standard of care (SOC) HIV prevention services in line with the South African DoH PrEP rollout program that include daily oral TDF/FTC. In addition, risk reduction counseling, IPV screening using the VAWS with referrals for counseling, medical care, or shelter assistance, among other care options if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered; 2. CHARISMA Intervention: SOC per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable: * Module A: General Partner Communication and Relationship Skills * Module B: Partner Disclosure and Communication around PrEP Use * Module C: Responding to Intimate Partner Violence and Safety Planning Population: Approximately four hundred sexually active, HIV-uninfected women who are trial naïve, non-pregnant, and not planning to be pregnant for the next six months, non-breastfeeding, aged 18 to 45 years of age (inclusive) Study Site(s): Wits RHI (Reproductive Health and HIV Institute) Clinical Research Site, Johannesburg, South Africa Other site(s) to be determined Approach: This project will offer a PrEP delivery package within two arms of a controlled, randomized study of women to evaluate the impact of the CHARISMA intervention when paired with PrEP delivery. Study Duration: Accrual will require approximately 12 months. Each participant presenting for PrEP education and services will be enrolled and followed for 6 months. Participants in both study arms will participate in scheduled visits for screening, enrollment, and months 1, 3, and 6 of follow-up. A subset of participants will be asked to participate in a qualitative interview at month 6, and/or month 9. Primary Objectives: 1. To determine the effectiveness of the CHARISMA intervention in increasing PrEP adherence/persistence at month 6; 2. To determine the effectiveness of the CHARISMA intervention in reducing reported experiences of social harms while on PrEP; 3. To determine the effectiveness of the CHARISMA intervention in reducing reported experiences of IPV (irrespective of time on PrEP); 4. To determine the effectiveness of CHARISMA on participant's reported relationship dynamics, including disclosure of PrEP use, support for product use, and communication; Secondary Objective: 5. To explore the acceptability and feasibility of the CHARISMA intervention; and Exploratory Objective: 7\) To assess the sensitivity and specificity of a brief IPV screening tool compared to a longer validated tool in identifying cases of IPV.

Interventions

OTHERControl

Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered

BEHAVIORALCHARISMA Intervention

SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable: * Module A: General Partner Communication and Relationship Skills * Module B: Partner Disclosure and Communication around PrEP Use * Module C: Responding to Intimate Partner Violence and Safety Planning

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

Two-arm, randomized (1:1), controlled study of a behavioral intervention to increase adherence to daily oral PrEP, improve partner relationships (communication and support) and reduce social harms and IPV.

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Able and willing to provide written informed consent and locator information * Reports having a current male primary partner, * Sexually active, defined by vaginal intercourse with a male at least 4 times per month in the past 3 months and plan to be sexually active during the study duration * Not pregnant (defined by urine pregnancy testing) and not breastfeeding * Not planning on becoming pregnant in the next 6 months * English or Zulu speaking * HIV negative based on negative HIV rapid tests, at the time of enrollment

Exclusion criteria

* Previously participated in a clinical trial or a longitudinal HIV prevention research study * Unwilling to use daily oral PrEP * Has any significant medical condition or other condition that, in the opinion of the Principal Investigator (PI)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Design outcomes

Primary

Measure	Time frame	Description
PrEP adherence/persistence by measurement	3 months	Adherence will be ascertained through measurement of TFV-DP (tenofovir-diphosphate) in dried blood spot (DBS) specimens. DBS collected via blood draw at Month 3 and 6 follow-up visits will be used for retrospective PCR testing for tenofovir levels (although DBS is collected at Enrollment and Month 1 as well).
PrEP adherence/persistence by self-report	3 months	Self-reported data on PrEP adherence will be collected via standardized questionnaires to better understand patterns of PrEP use and reasons for poor adherence or discontinuation. The tool used for the assessment is the WHO Violence Against Women Survey (VAWS). VAWS consists of behavior-specific items related to psychological (four items), physical (six items) and sexual violence (three items). The physical violence items are further divided into 'moderate' (the two first items) and 'severe' (the following four items) violence based on the likelihood of physical injury. Values are considered worse as responses to experiences of violence increase from no=0, to one=1, few=2, and many=3 times.
Incidence of social harms (SHs) using a SHs questionnaire	Anytime during the study, up to 6 months	SH in this study could include negative consequences related to study participation, PrEP use disclosure, stigma, gender-based violence, and relationship problems. Participants will be screened for SH resulting from product use or study participation at Enrollment, Month 3, and Month 6, and may report a social harm to staff at any time during the study.
IPV: Self-report of a) any IPV or b) physical or sexual IPV during study participation.	Anytime during the study, up to 6 months	All participants will receive SOC IPV screening at enrollment and at the Month 3 and Month 6 visits and may report IPV to staff at any time during the study. SOC IPV screening will include clinical screening with a validated IPV measurement tool-the WHO VAWS. The WHO considers the VAWS to be a valid and reliable measure of GBV (gender-based violence) and is therefore a reasonable SOC screening tool for this study.
Percent of participants who disclosed PrEP product use to a partner, which is reported via a questionnaire	Enrollment	Consistent with the primary objective to determine the effect of CHARISMA on participants' relationship dynamics, the following endpoints will be assessed: * Disclosure of PrEP use to male partners: Self-report that participants have told their partners that they are using PrEP * Male partner support for product use: Self-report that male partners support or accept (i.e. do not oppose) their PrEP use * Communication with male partners: Self-report of partnership communication dynamics. All participants will be asked about relationship dynamics, including disclosure of PrEP use, support for product use, and communication during enrollment, month 3, and 6 follow-up visits, and as needed during month 1 visits.

Secondary

Measure	Time frame	Description
Feasibility of the CHARISMA intervention - Percentage of missing data	Anytime during the study, up to 6 months	Consistent with the secondary objective to explore the acceptability and feasibility of CHARISMA, the following endpoint will be assessed: • Feasibility: Process indicator of percentage of missing HEART data.
Acceptability and feasibility assessed by intervention tool utilization as reported in response to a questionnaire.-	6 months	Consistent with the secondary objective to explore the acceptability and feasibility of CHARISMA, the following endpoint will be assessed: • Acceptability: Participant ranking of intervention components
Sensitivity and specificity of a brief IPV screening tool compared to a longer validated tool in identifying cases of IPV.	6 months	All participants will receive IPV screening at enrollment and at the Month 3 and Month 6 visits. SOC IPV screening will include clinical screening with a validated IPV measurement tool-the WHO VAWS. The WHO considers the VAWS to be a valid and reliable measure of GBV and is therefore a reasonable SOC screening tool for this study.
Sensitivity and specificity of a brief intimate partner violence (IPV) screening tool compared to a longer validated tool in identifying cases of IPV.	3 months	All participants will receive IPV screening at enrollment and at the Month 3 and Month 6 visits. SOC IPV screening will include clinical screening with a validated IPV measurement tool-the WHO VAWS. The WHO considers the VAWS to be a valid and reliable measure of GBV and is therefore a reasonable SOC screening tool for this study.
Acceptability and feasibility assessed by participants' accounts of utilizing the CHARISMA intervention, as reported during an interview.	6 months	Consistent with the secondary objective to explore the acceptability and feasibility of CHARISMA, the following endpoint will be assessed: • Acceptability: Participant qualitative report via interview
Feasibility of the CHARISMA intervention - Time to completion	Anytime during the study, up to 6 months	Consistent with the secondary objective to explore the acceptability and feasibility of CHARISMA, the following endpoint will be assessed: • Feasibility: Process indicator of time to completion.
Percentage of participants who complete the intervention as outlined by the protocol, assessed via case report forms	Anytime during the study, up to 6 months	Consistent with the secondary objective to explore the acceptability and feasibility of CHARISMA, the following endpoint will be assessed: • Feasibility: Process indicator of intervention fidelity
Feasibility of the CHARISMA intervention - Measure of surveys and modules completed	Anytime during the study, up to 6 months	Consistent with the secondary objective to explore the acceptability and feasibility of CHARISMA, the following endpoint will be assessed: • Feasibility: Process indicator of percentage of surveys and modules completed

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026